REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedClinical Trial

Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity.

Leung Daniel, Mu Xiaofeng, Duque Jaime S Rosa, Cheng Samuel M S, Wang Manni, Zhang Wenyue, Zhang Yanmei, Tam Issan Y S, Lee Toby S S, Lam Jennifer H Y
Frontiers in immunology2022DOI: 10.3389/fimmu.2022.982155

Citations

0

Subjects

Non-Human

Study Context

This clinical trial followed a structured protocol to evaluate outcomes. The controlled methodology adds credibility to the reported results.

Citation

Leung Daniel, Mu Xiaofeng, Duque Jaime S Rosa et al.. (2022). Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2022.982155

View full text on PubMed

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.